Logo

Biogen's BIIB112 (cotoretigene toliparvovec) Fails to Meet its Primary Endpoint in P-II/III XIRIUS Study for XLRP

Share this

Biogen's BIIB112 (cotoretigene toliparvovec) Fails to Meet its Primary Endpoint in P-II/III XIRIUS Study for XLRP

Shots:

  • The P-II/III XIRIUS study involves assessing subretinal injection of cotoretigene toliparvovec in males with a genetically confirmed diagnosis of XLRP. Part 1 of the study was a 24mos. dose-escalation study while part II was a 12mos. dose expansion study with a high & low dose selected from part I based on a benefit/risk assessment
  • The study failed to meet its 1EPs demonstrating improvement in the proportion of treated study eyes with ≥7 dB improvement from baseline at ≥5 of the 16 central loci of the 10-2 grid assessed by MAIA microperimetry
  • BIIB112 is an investigational AAV8 vector-based gene therapy to provide full-length functioning RPGR protein in patients with XLRP

  Ref: GlobeNewswire | Image: Biogen

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions